Understanding cross-resistance: A microbiological and epidemiological perspective – by Ana Cristina Gales
more
Do antibiotic combinations proposed from in vitro studies lead to changes in treatments? – by Angela Huttner
more
Crippling Gram-negative bacterial efflux of antibiotics – by Marion Flipo and Ruben C. Hartkoorn
more
How can we close the early discovery gap and improve our ability to discover new antibiotics? – by Olga Genilloud
more
Critically needed new antibacterial drugs for children with drug-resistant infections: How regulatory advancements can help – by Sumati ...
more
AMR and the need for new and old treatments for drug-resistant infections in LMICs – by Samuel Kariuki, Robert Onsare and Evelyn Wesangula ...
more
Targeting WHO priority pathogens to reduce mortality caused by neonatal sepsis – by Kajal Jain, Vivek Kumar, M Jeeva Sankar and Ramesh ...
more
Driving toward solutions to reduce antimicrobial manufacturing pollution – by Andrew C. Singer
more
Ongoing initiatives against antibiotic shortages – National, regional and global mechanisms to improve access to antibiotics – by Enrico ...
more
Targeting bacterial virulence to tackle the antimicrobial resistance crisis – by Ronan R. McCarthy
more
Who will protect the sheep from the wolves? – The increasing urgent need for antimicrobial stewardship worldwide – by Debra A. Goff ...
more
Bioinspired peptides as an alternative strategy for controlling multidrug-resistant bacteria – by Octávio Luiz Franco
more
The value of diagnostics in the fight against antimicrobial resistance – by Rosanna W. Peeling, David L. Heymann & Debi Boeras
more
Sulbactam plus durlobactam: a new addition to antibacterial therapies – by Ursula Theuretzbacher
more
The end of the pipeline is dry: major gaps in the clinical evidence required to inform clinical and country-level appraisal and use of newly ...
more
Plasmid-mediated resistance in the gonococcus and the use of post-exposure prophylaxis to prevent bacterial STIs – by Christoph M. Tang, ...
more
Nonclinical evidence for drug effectiveness can support streamlined antibacterial drug development – by Tina Guina and Edward A. Weinstein ...
more
Putting the Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act under the microscope – by Jacob Madden, Timo ...
more
The emerging field of digital antibiotic discovery – by Shuangzhe Lin & César de la Fuente
more
Market stimulation needed for predictable supply of antibiotics with vulnerable supply chains in Europe – by Christine Årdal
more
Access to industry antimicrobial resistance (AMR) susceptibility surveillance data – by Rebecca Li & Patricia Bradford
more
Lack of access to generic antibiotics and antifungals is an overlooked issue in AMR – by Fatema Rafiqi, Moska Hellamand and Martijn van ...
more
Improving our ability to discover new antibiotics – a chemist’s overview – by Mark Blaskovich
more
Making matters worse: antimicrobial resistance in conflict settings – by Jacob Goldberg, Angela Uyen-Cateriano and Gijs Van Gassen
more
Global antibiotic use patterns in children – by Julia A. Bielicki and Victor Musiime
more
Antifungal resistance monitoring, be aware and be prepared! – by Stephen Hawser and Ian Morrissey
more
The non-profit future of antibacterial R&D – by Brad Spellberg
more
One-health approach: Can antifungal resistance arise in the environment? – by Rafael W. Bastos and Gustavo H. Goldman
more
Addressing antimicrobial resistance for better care in cancer patients – by Yehoda M. Martei and Shalini J. Zürn
more
Trials of COVID-19 vaccines: what can be learnt for the development of new antimicrobials? – by Stephen Senn
more
Strengthening the regulation of antimicrobial use to mitigate drug resistance – by Maarten van der Heijden
more
Addressing the knowledge gaps surrounding AMR infections in neonatal sepsis – by Phoebe Williams, Nina Putri and Gayana Gunaratna
more
Rapid diagnostic tests to support clinical trials of antibiotics – by Gian Maria Rossolini
more
Will new antibiotic classes solve multidrug resistance? – by Michael N. Dudley and Olga Lomovskaya
more
Introducing ProMED-AMR, the new ProMED network for antimicrobial resistance – by Matthew E. Levison
more
Causes of antibiotic shortages and the solutions to address them – by Enrico Baraldi
more
Monitoring antimicrobial resistance in Ghana: a focus on the hospital environment – by Abiola Isawumi and Lydia Mosi
more
Learning from IPC strategies for COVID-19 to mitigate AMR in rural Nigerian communities – by Rachael Osagie
more
The antibiotic R&D landscape in Japan – by Norio Ohmagari
more
Tackling the drug-resistance pandemic – 2020 and beyond – by Laura J.V. Piddock
more
Why are new antibacterials failing as commercial products? – by Patricia A. Bradford
more
COVID-19: Coinfection, secondary bacterial infections and AMR in India – by Venkatasubramanian Ramasubramanian
more
Running a phase 3 trial for a new drug for gonorrhoea during the coronavirus pandemic – by Markus Heep, Esther Bettiol, Tanyaporn Wansom ...
more
